Monte Rosa Therapeutics, Inc. financial data

Symbol
GLUE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
321 Harrison Avenue, Suite 900, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 638 % -52.5%
Debt-to-equity 50.9 % +112%
Return On Equity -74.1 % -76.2%
Return On Assets -49.1 % -44.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.2 M shares +1.61%
Common Stock, Shares, Outstanding 50.2 M shares +1.7%
Entity Public Float 234 M USD -22.6%
Common Stock, Value, Issued 5 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 60.2 M shares +21.9%
Weighted Average Number of Shares Outstanding, Diluted 60.2 M shares +21.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 112 M USD +18.8%
General and Administrative Expense 33.5 M USD +17.9%
Operating Income (Loss) -144 M USD -17.7%
Nonoperating Income (Expense) 9.14 M USD +59.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -135 M USD +0.48%
Income Tax Expense (Benefit) 421 K USD
Net Income (Loss) Attributable to Parent -135 M USD -16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 99.8 M USD +92.4%
Assets, Current 199 M USD -17.3%
Property, Plant and Equipment, Net 34 M USD +0.69%
Operating Lease, Right-of-Use Asset 28.4 M USD -6.92%
Other Assets, Noncurrent 389 K USD +10.8%
Assets 267 M USD -13.7%
Accounts Payable, Current 6.83 M USD -7.51%
Employee-related Liabilities, Current 3.54 M USD +11.5%
Liabilities, Current 41.3 M USD +101%
Operating Lease, Liability, Noncurrent 41.8 M USD -3.32%
Liabilities 114 M USD +74.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.69 M USD -93.3%
Retained Earnings (Accumulated Deficit) -398 M USD -51.5%
Stockholders' Equity Attributable to Parent 153 M USD -37.4%
Liabilities and Equity 267 M USD -13.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2 M USD -63.1%
Net Cash Provided by (Used in) Financing Activities 246 K USD +1267%
Net Cash Provided by (Used in) Investing Activities 9.85 M USD -51.5%
Common Stock, Shares Authorized 500 M shares 0%
Common Stock, Shares, Issued 50.2 M shares +1.54%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -28.1 M USD -817%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 105 M USD +83.1%
Deferred Tax Assets, Valuation Allowance 54.5 M USD +64.6%
Deferred Tax Assets, Gross 66.6 M USD +43.8%
Operating Lease, Liability 5.4 M USD
Depreciation 6.97 M USD +68.2%
Payments to Acquire Property, Plant, and Equipment 1.38 M USD -84.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -137 M USD -17.9%
Property, Plant and Equipment, Gross 48.2 M USD +4.63%
Operating Lease, Liability, Current 3.35 M USD +15.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 41.9 M USD +60.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 4.48 M USD +100%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 6.4 M USD
Amortization of Intangible Assets 800 K USD 0%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 6.2 M USD
Deferred Tax Assets, Net of Valuation Allowance 12.2 M USD -8.16%
Share-based Payment Arrangement, Expense 4.87 M USD +22.6%
Operating Leases, Future Minimum Payments, Due in Three Years 6.6 M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%